Efficiency and Safety of HAIC Combined with Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma with Lung Metastasis: A Multicenter Propensity Score Matching Analysis
HAIC combined with lenvatinib and PD-1 inhibitor shows promise as a treatment for advanced HCC with lung metastases, offering improved prognosis and a manageable safety profile.
Authors
- Shuang‐Yan Tang (ORCID: https://orcid.org/0000-0002-1056-8690)
- Hongjie Cai (ORCID: https://orcid.org/0000-0001-9666-3172)
- Yi Xiao (ORCID: https://orcid.org/0000-0001-5315-7771)
- Xiongying Jiang (ORCID: https://orcid.org/0000-0003-4488-9326)
- Ning Wang (ORCID: https://orcid.org/0000-0003-1410-329X)
- Song Chen (ORCID: https://orcid.org/0000-0001-6412-5740)
- Wenbo Guo (ORCID: https://orcid.org/0000-0002-4343-6002)
- Feng Shi (ORCID: https://orcid.org/0000-0003-3509-3473)
- Wenquan Zhuang (ORCID: https://orcid.org/0000-0002-6384-2489)
Institutions
- Sun Yat-sen University (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Guangdong Provincial People's Hospital (CN)
- Eighth Affiliated Hospital of Sun Yat-sen University
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2025-09-01
- DOI
- https://doi.org/10.2147/itt.s542811
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- National Natural Science Foundation of China